Discover and read the best of Twitter Threads about #mmMRD
Most recents (2)
I get asked all the time: Can MRD status guide treatment decision in myeloma?
📜A separate thread dedicated to #ASH22 studies investigating #mmMRD-guided management in myeloma.
I will post lots more about our MRD2STOP study as we get closer to the conference! #mmsm
📜A separate thread dedicated to #ASH22 studies investigating #mmMRD-guided management in myeloma.
I will post lots more about our MRD2STOP study as we get closer to the conference! #mmsm
Abstract 992 (@kordeneha1):
The premise: Patients with 3+ years of MRD-neg (flow, 10^-5 to 10^-6) undergo discontinuation of maintenance. Monitored q6mos bone marrow (flow), yearly PET.
n=23
👍Sustained MRD-neg at 12 months: 14/16 (88%)
👍12 month PFS: 94%
ashpublications.org/blood/article/…
The premise: Patients with 3+ years of MRD-neg (flow, 10^-5 to 10^-6) undergo discontinuation of maintenance. Monitored q6mos bone marrow (flow), yearly PET.
n=23
👍Sustained MRD-neg at 12 months: 14/16 (88%)
👍12 month PFS: 94%
ashpublications.org/blood/article/…
Abstract 3237 (@End_myeloma) Update from MASTER trial (MRD-Adapted Dara-KRd + ASCT):
#⃣84 pts in treatment-free surveillance, f/u ~24 mos.
👉8% MRD resurgence, 13% disease progression
☀️79% still off treatment
⚠️Only 47% of ultra-high risk pts off therapy
ash.confex.com/ash/2022/webpr…
#⃣84 pts in treatment-free surveillance, f/u ~24 mos.
👉8% MRD resurgence, 13% disease progression
☀️79% still off treatment
⚠️Only 47% of ultra-high risk pts off therapy
ash.confex.com/ash/2022/webpr…
So many excellent #ASH22 abstracts to choose from. Sharing my thoughts on 11 important works, with more to come as we get closer to the meeting! In order of abstract number (not merit)...let's go! #mmsm
158: Elrantamab in R/R MM to be presented by @NoopurRajeMD.
☀️27% Black or asian enrollment
☀️ 24% with prior BCMA-dir therapy
👉ORR 64% (38% CR+)
🚨7/13 (54%) ORR w/prior BCMA-dir therapy. This is the important take home!
⏳Duration of response 17 months
ash.confex.com/ash/2022/webpr…
☀️27% Black or asian enrollment
☀️ 24% with prior BCMA-dir therapy
👉ORR 64% (38% CR+)
🚨7/13 (54%) ORR w/prior BCMA-dir therapy. This is the important take home!
⏳Duration of response 17 months
ash.confex.com/ash/2022/webpr…
160: MajesTEC-2: Teclistamab/Len/Dara (Searle).
n=32; f/u 6 months. Median 2 prior lines. 31% anti-CD38 exposed.
⚠️Infections 75% (respiratory). CRS 81% (gr 1-2)
🚨 ORR 100% (VGPR 12/13).
So important to establish whether bispecifics can play nice with other myeloma therapies.
n=32; f/u 6 months. Median 2 prior lines. 31% anti-CD38 exposed.
⚠️Infections 75% (respiratory). CRS 81% (gr 1-2)
🚨 ORR 100% (VGPR 12/13).
So important to establish whether bispecifics can play nice with other myeloma therapies.
